**Core Concept:** Carbimazole is a medication used to treat hyperthyroidism by inhibiting thyroid hormone synthesis. It is a prodrug that is converted into its active form, methimazole, by the liver. During pregnancy, carbimazole crosses the placenta and can affect the developing fetus.

**Why the Correct Answer is Right:** Carbimazole is a prodrug that gets converted into methimazole, which suppresses thyroid hormone synthesis. In the neonate, the liver is not fully developed, leading to reduced conversion of carbimazole into methimazole. As a result, methimazole levels in the neonate are lower than in the mother, which reduces the risk of hypothyroidism in the neonate.

**Why Each Wrong Option is Incorrect:**

A. This option is incorrect due to the fact that hypothyroidism is a potential side effect in neonates due to reduced conversion of carbimazole into methimazole.

B. This option is incorrect because neonates may experience hypothyroidism due to reduced conversion of carbimazole into methimazole.

C. This option is incorrect because neonates may experience hypothyroidism due to reduced conversion of carbimazole into methimazole.

D. This option is incorrect because neonates may experience hypothyroidism due to reduced conversion of carbimazole into methimazole.

**Clinical Pearl:** In cases where a pregnant patient requires antithyroid medication, methimazole is preferred over carbimazole due to its higher bioavailability and better safety profile in neonates. However, in cases where methimazole is not available or not approved for use in pregnancy, carbimazole can be used. In either case, close monitoring of the neonate for signs of hypothyroidism is essential, especially in cases of prolonged maternal therapy.